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Abstract
Background: For patients with reflux esophagitis (RE), endoscopic findings alone (without the frequency and
severity of symptoms) may not fully reflect the associated impact on health-related quality of life (QOL). There is
not enough data about symptoms and QOL of Japanese patients with RE. The present study therefore investigated
the epidemiological characteristics of such patients, and evaluated the efficacy and safety of omeprazole (and
other gastrointestinal drugs, except proton pump inhibitors [PPIs]) in terms of improving patients’ symptoms and
QOL.
Methods: In a large-scale, specific clinical experience investigation of Japanese patients with RE, epidemiological
characteristics, QOL and symptoms of the disease in relation to treatment with omeprazole and other
gastrointestinal drugs, except PPIs, and safety data of omeprazole were collected. The Quality Of Life in Reflux and
Dyspepsia questionnaire (QOLRAD) was used for QOL assessment.
Results: 9967 patients were included in the analysis (omeprazole: 7888). At baseline, 75.2% of patients had three or
more upper gastrointestinal symptoms, and 31.5% of patients had six or more upper gastrointestinal symptoms.
The overall mean QOLRAD score at baseline was 5.14 (the best score is 7). In the omeprazole group, the rate of
satisfactory improvement in subjective symptoms was 61.7% and 81.8% at Weeks 4 and 8, respectively, and these
were both significantly higher than those of patients treated with other drugs. In both the omeprazole group and
the other drugs group, the QOLRAD score at Week 4 improved significantly from baseline, and the degree of
improvement was significantly greater in the omeprazole group than in the other drugs group. The favourable
tolerability profile of omeprazole was confirmed.
Conclusion: In a large-scale survey, omeprazole improved symptoms and QOL more effectively in Japanese
patients with RE than other investigated drugs, and had a good tolerability profile.
Trial Registration: ClinicalTrials.gov identifier: NCT00859287.
Background
In the evaluation of clinical efficacy, subjective outcomes
are now being regarded as very important, and patient-
based clinical outcome measures are being required in
addition to conventional indices of pathological changes.
For reflux esophagitis (RE) in particular, some reports
have shown that endoscopic findings do not correspond
to the frequency and severity of symptoms [1] and that
the health-related quality of life (QOL) of patients with
RE is as impaired as that of patients with angina pec-
toris [2]. Elsewhere, in recent studies in Japan, the fre-
quency of symptoms and the severity of endoscopic
findings were associated [3,4]. Nonetheless, assessing
QOL is an important facet of evaluating clinical
treatments.
Various scales and questionnaires have been developed
to assess QOL, including the MOS Short-form Health
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any medium, provided the original work is properly cited.Survey (SF-36) [5] as a health profile scale, the Psycho-
logical General Well-Being scale (PGWB) [6] to measure
psychosocial factors, the Gastrointestinal Symptom Rat-
ing Scale (GSRS) [7] to evaluate general gastrointestinal
symptoms, and the Quality Of Life in Reflux And Dys-
pepsia (QOLRAD) questionnaire [8] as a disease-specific
questionnaire for RE.
QOLRAD-J, the Japanese version of QOLRAD, was
recently developed and validated for assessment of QOL
in Japanese patients with heartburn [9]. The QOLRAD-J
consists of 25 questions grouped into five domains
(emotional distress, sleep disturbance, food/drink pro-
blems, physical/social functioning, and vitality) that are
strongly related to acid reflux symptoms. Each domain
is scored using a scale from 1 (worst condition) to 7
(best condition). A quantitative psychological evaluation
of the QOLRAD-J in Japanese patients with heartburn
demonstrated sufficient reliability, validity and
distinctiveness.
It has been described that the prevalence of upper
abdominal symptoms such as heartburn is high and
QOL is significantly impaired in patients with gastroeso-
phageal reflux disease (GERD), including RE [10,11].
Nevertheless, no large-scale epidemiological survey has
been conducted in Japan to assess the symptoms or
QOL of patients with heartburn or other syndromes, or
the relationship between patient characteristics and
treatment. Thus, we used the QOLRAD-J and a ques-
tionnaire to record clinical symptoms and evaluate the
efficacy and safety of omeprazole in the treatment of
RE. This report describes the QOL and symptoms of
Japanese patients with RE, as well as changes in their
QOL and symptoms after treatment with omeprazole or
other gastrointestinal drugs, except for proton pump
inhibitors (PPIs), and the safety profile of omeprazole.
Methods
Objectives
The objectives of this investigation were to epidemiologi-
cally analyze the background factors, clinical symptoms
and QOL of patients with RE using the QOLRAD-J ques-
tionnaire as part of usual clinical practice in Japan, and
to evaluate the effects of omeprazole on their symptoms
and QOL; the safety and tolerability of omeprazole was
also determined. Other non-PPI gastrointestinal drugs
(subsequently referred to as ‘other drugs’;s e ed e t a i l s
below) were also evaluated in terms of their effects on
symptoms and QOL of RE patients. This was a specific
investigation of clinical experience entitled OMAREE
(Omepral
® tablets Mega-study to investigate the efficacy
on various types of Acid Reflux related symptoms and
QOL, and epidemiology in patients with Erosive Esopha-
gitis in daily medical practice) and was conducted in
compliance with Good Postmarketing Study Practice and
Helsinki Declaration, and in accordance with the Perso-
nal Information Protection Law. The institutional review
board at Jinbo Orthopedics Clinic and the join institu-
tional review board at Keihin-Chuo Clinic, Hisamitsu
Clinic, and Masabayashi Clinic approved the study design
(Reference Study Number: D9584L00008). Study objec-
tives and design were explained and consent was
obtained from all patients. This study is registered with
ClinicalTrials.gov, number NCT00859287.
Patients
To be included in the investigation, patients had to be
receiving (either as initial therapy or maintenance therapy
for RE) or be newly started on omeprazole (Omepral
®
Tablet 10 or Omepral
® Tablet 20, AstraZeneca K.K.,
Japan) or other drugs but not within 4 weeks of study
initiation, have had acid reflux-related symptoms (e.g.,
heartburn) of any intensity for 2 days or more, or of mod-
erate to severe intensity for 1 day or more during 1 week
immediately before the start of the investigation, and be
able to complete the questionnaires to record symptoms
and QOLRAD-J. Endoscopic confirmation of the diagnosis
of RE was also required. Patients were excluded if they
had received PPI therapy within 4 weeks before the start
of the investigation, had been previously enrolled in this
investigation, or were contraindicated to treatment with
omeprazole according to the package insert. During the
investigation, all treatments were provided at the physi-
cian’s discretion and in an open-label manner. This inves-
tigation included also special patient populations such as
children, elderly patients, patients with renal dysfunction,
patients with hepatic dysfunction, or pregnant women.
Methods and outcome variables
The enrollment period of this investigation was between
June 2007 and May 2008, and patients were followed up
for 8 weeks. Five patients were enrolled per center.To
avoid an imbalance of patient characteristics between
the treatment groups, the patient who had been or
would be treated with other drugs was enrolled as the
first patient at each participating center, while the
patients who had been or would be treated with ome-
prazole were enrolled as the second to fifth patients.
On enrollment, the patient’s age, sex, height, body
weight, lifestyle, medical history, surgical history, prior
medication, Helicobacter pylori infection status, history
of the present illness, and QOL (measured using the
QOLRAD-J) were recorded. Symptoms were assessed by
both the investigators (i.e., physician-reported symp-
toms) and the patients (i.e., patient-reported symptoms).
The investigators recorded the chief complaint of the
patient, and its severity and frequency. The patients
recorded the type, severity and frequency of the symp-
toms, the chief complaint, and the area affected, directly
Yoshida et al. BMC Gastroenterology 2011, 11:15
http://www.biomedcentral.com/1471-230X/11/15
Page 2 of 13on the questionnaire form. Physician- and patient-
reported symptoms, and QOL were to recorded at
Weeks 4 and 8 of the investigation, based on recall
relating to the previous week. Patients in the omepra-
zole group were also monitored for any adverse drug
reactions (drug-related adverse events [as assessed by
the physician]) during the investigation period.
Statistical methods
The final analysis was conducted using patients for
whom data collection and data fixation had been com-
pleted as of March 31, 2009.
Patient background characteristics and clinical symp-
toms at baseline were summarized and descriptive sta-
tistics were calculated. For QOL, the QOLRAD-J scores
were calculated and, to verify the validity of the QOL-
RAD-J, Cronbach’s a coefficients for individual domains
and QOLRAD-J scores stratified by the severity and fre-
quency of physician-reported symptoms were calculated.
For each patient, if 50% or more of the items within a
specific domain of the QOLRAD-J were answered, the
mean score of the answered items was used as the
domain score; if less than 50% of the items were
answered within the domain, the domain score was
regarded as missing.
The primary endpoint for the efficacy assessment was
a satisfactory improvement in subjective symptoms at
Week 8, defined as physician-reported symptoms during
the preceding week being “None” or “Only mild symp-
toms for 1 day”. This definition was used throughout
the study. The secondary endpoints included a satisfac-
tory improvement in subjective symptoms at Week 4,
complete resolution of subjective symptoms (i.e., physi-
cian-reported symptoms during the preceding week
being “None”) at Weeks 4 and 8, satisfactory improve-
ment in individual patient-reported symptoms at Weeks
4 and 8, and QOLRAD scores before and after the start
of the investigation with stratification for physician-
reported symptom. The primary and secondary end-
points were compared between the groups, while also
compared between before and after the start of the
investigation.
Between-group comparisons of the rates of improve-
ment and resolution of symptoms were conducted using
c
2 tests. Between-group comparisons of QOLRAD score
were conducted using two-sample t tests, and the
change from baseline in the QOLRAD score within each
treatment group was analyzed using paired t tests with-
out multiplicity adjustment. A two-sided 5% significance
level was used for all statistical tests. For the evaluation
of safety and tolerability, the incidence of adverse drug
reactions in the omeprazole group was analyzed
descriptively.
In this study, enrolled patients will be divided into two
groups (omeprazole: other drugs = 4:1). The efficacy
rates of the primary endpoint were assumed to be 50%
and 45%, respectively, for the two groups. In order to
have 95% power to detect a difference in the efficacy
rates between the groups using a c
2 test with two-sided
5% significance level, 6472 omeprazole-treated patients
and 1618 patients for ‘other drugs’ was required. So, it
was necessary to enroll a total of at least 8090 patients.
Results
Patient characteristics
A total of 2143 medical institutions participated in this
investigation, and data were collected for 10,704
patients. The analysis set consisted of 9967 patients
(7888 patients received omeprazole and 2079 patients
received other drugs); 737 patients were excluded from
the analysis because of inappropriate enrollment, inabil-
ity to collect data or contract violation. The safety analy-
sis set consisted of 7711 patients treated with
omeprazole, as 177 patients did not return to the inves-
tigation site after enrollment and were excluded.
Table 1 shows the characteristics of the patients in the
analysis set. Overall, there was a slightly larger number
of women than men. The mean body mass index was
23.23 kg/m
2, showing no tendency for obesity. Concur-
rent conditions reported in ≥5% of patients included
hypertension (28.7%), hyperlipidemia (18.4%), chronic or
acute gastritis (15.4%), esophageal hiatus hernia (8.5%),
insomnia (7.6%), and diabetes mellitus (5.9%).
The duration of RE was reported as less than 3 months
in 62.6% of patients, and was 6 months or more in 27.8%
of patients. In terms of the drugs used during the
4 weeks before the start of the investigation (patients
using PPIs during this time were excluded), H2 blockers
were the most commonly used (15.2%). When we investi-
gated the previous 5 years, 17.7% of patients had a history
of PPI therapy.
In patients treated with other drugs, the most com-
monly used agents were H2 blockers (1895 patients,
91.2%), prokinetics (490 patients, 23.6%), and mucosal
protectants (435 patients, 20.9%).
Clinical symptoms and QOL at baseline
Table 2 shows the frequency and severity of physician-
reported symptoms at baseline. Moderate or severe
symptoms were reported for 57.5% of patients. The ratio
of patients with moderate or severe symptoms in the
omeprazole group was slightly higher than in the other
drugs group. 41.4% of patients were symptomatic almost
every day.
Figure 1 summarizes the specific patient-reported
symptoms at baseline. “Stomach pain”, “heavy feeling in
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Page 3 of 13Table 1 Demographic and baseline characteristics
Total
(N = 9967)
Omeprazole
(N = 7888)
Other drugs
(N = 2079)
Age < 40 years 1503 (15.1) 1169 (14.8) 334 (16.1)
≥40 - <65 years 3929 (39.4) 3107 (39.4) 822 (39.5)
≥65 years 4535 (45.5) 3612 (45.8) 923 (44.4)
Sex Men 4178 (41.9) 3246 (41.2) 932 (44.8)
Women 5789 (58.1) 4642 (58.9) 1147 (55.2)
Body mass index, kg/m
2 < 18.5 404 (4.1) 301 (3.8) 103 (5.0)
≥18.5 - <25 4134 (41.5) 3234 (41.0) 900 (43.3)
≥25 1786 (17.9) 1378 (17.5) 408 (19.6)
Unknown 3643 (36.6) 2975 (37.7) 668 (32.1)
Habitual smoking No 7310 (73.3) 5744 (72.8) 1566 (75.3)
Yes 1685 (16.9) 1333 (16.9) 352 (16.9)
Unknown/not specified 972 (9.8) 811 (10.3) 161 (7.7)
Habitual alcohol consumption No 5777 (58.0) 4608 (58.4) 1169 (56.2)
Yes 3180 (31.9) 2444 (31.0) 736 (35.4)
Unknown/not specified 1010 (10.1) 836 (10.6) 174 (8.4)
H. pylori eradication No 5712 (57.3) 4503 (57.1) 1209 (58.2)
Yes 583 (5.9) 454 (5.8) 129 (6.2)
Unknown 3672 (36.8) 2931 (37.2) 741 (35.6)
H. pylori infection No 3003 (30.1) 2348 (29.8) 655 (31.5)
Yes 513 (5.2) 415 (5.3) 98 (4.71)
Unknown/not specified 6451 (64.7) 5125 (65.0) 1326 (63.8)
Past and concurrent diseases (reported in ≥5% patients)
Past disease No 8480 (85.1) 6763 (85.7) 1717 (82.6)
Yes 1487 (14.9) 1125 (14.3) 362 (17.4)
Concurrent disease No 3789 (38.0) 2940 (37.3) 849 (40.8)
Yes 6178 (62.0) 4948 (62.7) 1230 (59.2)
Esophageal hiatus hernia Past disease 26 (0.3) 19 (0.2) 7 (0.3)
Concurrent disease 844 (8.5) 690 (8.8) 154 (7.4)
Gastritis (chronic/acute) Past disease 258 (2.6) 190 (2.4) 68 (3.3)
Concurrent disease 1536 (15.4) 1278 (16.2) 258 (12.4)
Diabetes mellitus Past disease 45 (0.5) 32 (0.4) 13 (0.6)
Concurrent disease 586 (5.9) 463 (5.9) 123 (5.9)
Hyperlipidaemia Past disease 129 (1.3) 98 (1.2) 31 (1.5)
Concurrent disease 1831 (18.4) 1477 (18.7) 354 (17.0)
Hypertension Past disease 151 (1.5) 120 (1.5) 31 (1.5)
Concurrent disease 2860 (28.7) 2290 (29.0) 570 (27.4)
Insomnia Past disease 48 (0.5) 36 (0.5) 12 (0.6)
Concurrent disease 756 (7.6) 592 (7.5) 164 (7.9)
Duration of RE
< 3 months 6236 (62.6) 5041 (63.9) 1195 (57.5)
≥3 - <6 months 963 (9.7) 776 (9.8) 187 (9.0)
≥6 months 2767 (27.8) 2070 (26.2) 697 (33.5)
Not specified 1 (0) 1 (0) 0 (0)
Prior treatment for RE
Treatment for RE during the 4 weeks prior to the investigation No 7769 (78.0) 6218 (78.8) 1551 (74.6)
Yes 2007 (20.1) 1532 (19.4) 475 (22.9)
H2 blockers 1519 (15.2) 1161 (14.7) 358 (17.2)
Prokinetics 509 (5.1) 391 (5.0) 118 (5.7)
Antacids 197 (2.0) 151 (1.9) 46 (2.2)
Mucosal protectants 536 (5.4) 410 (5.2) 126 (6.1)
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Page 4 of 13the stomach”, “nausea”, “acid or bitter taste due to
refluxed fluid”, and “belching” were reported by ≥40% of
patients. Approximately one third of patients com-
plained of a “burning sensation towards the neck” as the
typical symptom of heartburn. Three or more symptoms
were reported by 75.2% of patients, and six or more
symptoms were reported by 31.5% of patients.
Figure 2 shows the scores for each domain of the
QOLRAD at baseline for all patients. The overall mean
score of the omeprazole and comparator groups was
similar: 5.14 and 5.22, respectively. Figure 3 shows the
scores stratified according to the severity of physician-
reported symptoms. The overall mean score (n = 9320)
was decreased (5.15), with prominent decreases in the
emotional distress, food/drink problems, and vitality
domains. The overall mean score and the scores for the
individual domains were lower in patients with greater
severity, frequency or number of symptoms (Figures 3, 4
and 5). QOLRAD item scores are shown in Figure 6.
The Cronbach’s a coefficients for individual domains at
baseline were 0.93 for emotional distress, 0.91 for sleep
disturbance, 0.89 for food/drink problems, 0.90 for phy-
sical/social functioning, and 0.82 for vitality.
Changes in clinical symptoms and QOL during the
investigation
Change in symptoms
Among patients treated with omeprazole, satisfactory
improvement in subjective symptoms was observed in
61.7% and 81.8% of patients at Weeks 4 and 8, respec-
tively, and these percentages were both significantly
higher than those of patients treated with other drugs
(Table 3). In addition, the percentage of patients with
complete resolution of subjective symptoms at Weeks 4
and 8 was 44.0% and 67.2%, respectively, in patients
treated with omeprazole, versus 27.3% and 46.0%,
respectively, in patients treated with other drugs, show-
ing significant between-group differences at both Weeks
4 and 8 (Table 4).
The rate of improvement of patient-reported symp-
toms at Week 8 was significantly higher for patients
treated with omeprazole than for patients treated with
other drugs for symptoms other than “irritating sensa-
tion in the throat” and “coughing” (Table 5).
Change in QOL
In both the omeprazole and other drugs group, the overall
mean QOLRAD score and the QOLRAD scores for indivi-
dual domains at Week 4 improved significantly from base-
l i n e( F i g u r e7 ) .H o w e v e r ,t h ed e g r e eo fi m p r o v e m e n t
(change) was significantly greater in the omeprazole group
than in the other drugs group (Figure 8).
Table 1 Demographic and baseline characteristics (Continued)
Antianxiety drugs 101 (1.0) 69 (0.9) 32 (1.5)
Antidepressants 47 (0.5) 32 (0.4) 15 (0.7)
Chinese herbal medicines 59 (0.6) 37 (0.5) 22 (1.1)
Other drugs 95 (1.0) 71 (0.9) 24 (1.2)
Unknown 191 (1.9) 138 (1.8) 53 (2.6)
PPI use during the past 5 years
No 6953 (69.8) 5462 (69.2) 1491 (71.7)
Yes 1761 (17.7) 1444 (18.3) 317 (15.3)
< 6 months 809 (8.1) 663 (8.4) 146 (7.0)
≥6 months - <1 year 408 (4.1) 337 (4.3) 71 (3.4)
≥1 - <2 years 323 (3.2) 259 (3.3) 64 (3.1)
≥2 - <5 years 213 (2.1) 178 (2.3) 35 (1.7)
≥5 years 8 (0.1) 7 (0.1) 1 (0.1)
Unknown 1253 (12.6) 982 (12.5) 271 (13.0)
Values are n (%). RE = reflux esophagitis; PPI = proton pump inhibitor.
Table 2 Physician-reported symptoms at baseline
Total
(N = 9967)
Omeprazole
(N = 7888)
Other
drugs
(N = 2079)
Intensity (%)
Mild 4235 (42.5) 3127 (39.6) 1108 (53.3)
Moderate 5273 (52.9) 4351 (55.2) 922 (44.4)
Severe 459 (4.6) 410 (5.2) 49 (2.4)
Frequency
(%)
Not
specified
14 (0.1) 10 (0.1) 4 (0.2)
1 day 161 (1.6) 124 (1.6) 37 (1.8)
2 days 1348 (13.5) 993 (12.6) 355 (17.1)
3 days 1964 (19.7) 1528 (19.4) 436 (21.0)
4 days 1124 (11.3) 892 (11.3) 232 (11.2)
5 days 1230 (12.3) 984 (12.5) 246 (11.8)
6 days 327 (3.3) 271 (3.4) 56 (2.7)
7 days 3799 (38.1) 3086 (39.1) 713 (34.3)
Mean ± SD 4.8 ± 2.0 4.9 ± 2.0 4.6 ± 2.0
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Page 5 of 13Figure 1 Profile and intensity of patient-reported symptoms at baseline (N = 8985).
Figure 2 Mean (± SD) QOLRAD-J domain and total scores at baseline.
Figure 3 Mean (± SD) QOLRAD-J domain and total scores according to the intensity of physician-reported symptoms at baseline.
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Page 6 of 13Figure 4 Mean QOLRAD-J domain and total scores by frequency of symptoms at baseline.
Figure 5 Mean QOLRAD-J domain and total scores according to the number of patient-reported symptoms at baseline.
Figure 6 Mean QOLRAD-J item scores at baseline.
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Adverse drug reactions (adverse events related to ome-
prazole) are summarized in Table 6. Overall, 0.92% of
patients experienced adverse drug reactions, with no dif-
ferences in their incidence among different doses. The
most common adverse drug reactions were gastrointest-
inal disorders (0.35%) followed by skin and subcutaneous
tissue disorders (0.22%). Four serious adverse drug reac-
tions, namely intracranial venous sinus thrombosis, ver-
tigo, upper abdominal pain, and increased blood
pressure, were reported in one patient each.
Discussion
This is the first large-scale observational investigation
that prospectively assessed the changes in clinical symp-
toms and QOL over 8 weeks in Japanese RE patients
treated with omeprazole.
The QOL questionnaire used in this investigation, the
QOLRAD-J, was validated and found to be useful in 224
Japanese patients with heartburn [9]. In the present
investigation, the Cronbach’s a coefficients were calcu-
lated for the individual domains of the QOLRAD at
baseline to verify the reliability of the questionnaire in
patients with RE. Notably, the coefficients were quite
high (0.82-0.93) and were similar to those reported by
Hongo et al. (0.83-0.94) [9], supporting the internal con-
sistency within each domain. In addition, the severity of
physician-reported symptoms showed a negative correla-
tion with QOLRAD scores. Taken together, the QOL-
RAD-J was shown to be a reliable questionnaire to
assess QOL in Japanese patients with RE.
In an European study that followed 152 patients with
RE for 10 years and compared the QOL assessed using
the SF-36 between RE patients and the general popula-
tion, physical function and social function were reported
to be significantly lower in patients with RE [12].
According to a report by Talley et al., [13] the smallest
clinically meaningful change in score on the QOLRAD
is 0.5, with 1.0 regarded as an ‘important change’ and
1.5 as a ‘very important change’. In the present investi-
gation, the QOLRAD-J score at baseline was found to
be lower than the best possible score (7) by 1.5 or more
for all domains except physical/social functioning, and
low QOL scores were associated with the type, fre-
quency, severity, and number of symptoms. To date,
lesion healing has been the focus of treatment for RE;
however, the treatment of symptoms is also important
in terms of QOL improvement.
A close correlation has been found between QOL and
RE symptoms, and these patients also present with a
range of other symptoms. Adachi et al. reported that
acid reflux symptoms such as heartburn were present in
approximately 70% of patients with RE, concurrently
with stomach pain in 54% and a “heavy feeling in the
stomach” in 62% [14]. In the present investigation, a
“heavy feeling in the stomach” was the most commonly
reported symptom and its severity was higher than that
of other symptoms. In addition, ≥70% of the patients
had three or more symptoms. These results were consis-
tent with those reported by Adachi et al., [14] demon-
strating that patients with RE suffer not only typical
symptoms such as heartburn but also various other
symptoms, confirming the importance of evaluating
those symptoms during treatment. The baseline charac-
teristics of patients in our study were similar to those in
the earlier study [14], although fewer patients with BMI
>25 participated in our study (18% versus 30%). It is
possible that the nature and severity of symptoms might
vary among patient groups which differ significantly
with respect to baseline characteristics, from those stu-
died to date.
Omeprazole was more efficacious than other drugs in
improving RE symptoms in the present study. The effi-
cacy of PPIs in the treatment of upper gastrointestinal
symptoms has been demonstrated in Japanese and non-
Japanese studies. For example, in the CADET-HN study,
Table 3 Proportion of patients with satisfactory improvement in physician-reported symptoms
Omeprazole Other drugs Omeprazole - Other drugs
Improvement, % 95% CI Improvement, % 95% CI Difference 95% CI p-value*
Week 4 61.7 (3265/5291) (60.4, 63.0) 45.0 (631/1401) (42.4, 47.6) 16.7 (13.8, 19.6) < 0.001
Week 8 81.8 (3373/4123) (80.6, 83.0) 64.2 (697/1085) (61.4, 67.1) 17.6 (14.5, 20.7) < 0.001
* c
2 test. CI = confidence interval.
Table 4 Complete resolution of physician-reported symptoms
Omeprazole Other drugs Omeprazole - Other drugs
Resolution, % 95% CI Resolution, % 95% CI Difference 95% CI p-value*
Week 4 44.0 (2327/5291) (42.6, 45.3) 27.3 (383/1401) (25.0, 29.7) 16.6 (14.0, 19.3) < 0.001
Week 8 67.2 (2771/4123) (65.8, 68.6) 46.0 (499/1085) (43.0, 49.0) 21.2 (17.9, 24.5) < 0.001
* c
2 test. CI = confidence interval.
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Week 4 Week 8
Omeprazole
Improvement, %
Other drugs
Improvement, %
Difference
(95% CI)
p-value* Omeprazole
Improvement, %
Other drugs
Improvement, %
Difference
(95% CI)
p-value*
Stomach pain 71.7 (1107/1544) 64.1 (257/401) 7.6 (2.4, 12.8) 0.003 83.7 (1018/1216) 74.9 (230/307) 8.8 (3.5, 14.1) < 0.001
Heavy feeling in the stomach 61.7 (1467/2379) 45.9 (299/652) 15.8 (11.5, 20.1) < 0.001 77.0 (1465/1903) 64.0 (330/516) 13.0 (8.5, 17.6) < 0.001
Nausea 72.1 (1079/1497) 62.0 (246/397) 10.1 (4.8, 15.4) < 0.001 85.1 (1013/1191) 74.2 (227/306) 10.9 (5.6, 16.2) < 0.001
Irritating sensation in the throat 68.4 (726/1061) 69.1 (170/246) -0.7 (-7.1, 5.7) 0.836 77.8 (657/844) 71.4 (135/189) 6.4 (-0.6, 13.4) 0.059
Acid or bitter taste due to refluxed fluid 70.7 (1502/2124) 58.4 (320/548) 12.3 (7.8, 16.9) < 0.001 85.4 (1492/1747) 72.9 (315/432) 12.5 (8.0, 17.0) < 0.001
Stomach bloating sensation 66.4 (878/1322) 56.7 (202/356) 9.7 (3.9, 15.4) < 0.001 81.5 (882/1082) 74.0 (211/285) 7.5 (1.9, 13.1) 0.005
Choking sensation in the throat 66.8 (641/959) 64.7 (152/235) 2.2 (-4.6, 9.0) 0.530 78.6 (611/777) 68.9 (126/183) 9.8 (2.5, 17.1) 0.005
Burning sensation from stomach or lower chest
toward the neck
78.9 (1097/1391) 69.2 (225/325) 9.6 (4.2, 15.1) < 0.001 88.4 (989/1119) 77.0 (207/269) 11.4 (6.1, 16.8) < 0.001
Belching 60.7 (940/1548) 49.3 (197/400) 11.5 (6.0, 16.9) < 0.001 74.3 (947/1275) 64.4 (206/320) 9.9 (4.1, 15.7) < 0.001
Loss of appetite 75.4 (771/1022) 66.2 (178/269) 9.3 (3.0, 15.5) 0.002 85.3 (721/845) 75.1 (154/205) 10.2 (3.8, 16.6) < 0.001
Early satiety 68.8 (698/1015) 62.0 (178/287) 6.7 (0.5, 13.0) 0.031 80.5 (656/815) 72.0 (167/232) 8.5 (2.1, 14.9) 0.005
Coughing 62.9 (450/715) 58.9 (103/175) 4.1 (-4.0, 12.2) 0.319 74.6 (432/579) 68.7 (101/147) 5.9 (-2.4, 14.2) 0.148
* c
2 test. CI = confidence interval.
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treated with omeprazole, H2 blockers, prokinetics or pla-
cebo, and the results showed that omeprazole was sig-
nificantly more effective in improving symptoms [15].
Similarly, in the Japanese J-FOCUS study conducted
in a similar patient population, omeprazole elicited
significantly greater improvements in symptoms com-
pared with H2 blockers, prokinetics, and gastric
Figure 7 Mean (± SD) QOLRAD-J domain and total scores at baseline, and at Weeks 4 and 8.
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Page 10 of 13mucoprotective drugs [16]. The present investigation
further supports the results of these previous studies
demonstrating the usefulness of PPIs such as omepra-
zole in the treatment of upper abdominal symptoms.
At Week 8, patients treated with other drugs did not
show improvements in any QOLRAD domain by a
score of 1.5 or more (i.e., a ‘very important change’ as
described by Talley et al. [13]). By contrast, patients
treated with omeprazole showed improvements in scores
of 1.5 or more for the domains of emotional distress,
food/drink problems, and vitality, indicating the favour-
able efficacy of omeprazole in improving symptoms and,
in turn, QOL. Havelund et al. [17] compared changes in
QOL assessed using GSRS and PGWB after 4 weeks of
treatment with omeprazole (20 or 10 mg/day) or pla-
cebo in patients with heartburn but without esophagitis.
Both omeprazole groups showed significantly greater
improvements in QOL than the placebo group, and the
Figure 8 Mean (± SD) change in QOLRAD-J domain and total scores from baseline to Weeks 4 and 8.
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Page 11 of 13PGWB scores in the two omeprazole groups improved
to a level comparable with that of healthy individuals. In
addition, omeprazole elicited marked improvements in
the domains of anxiety, depression, and self-control
[17]. In the present investigation, there were marked
improvements in the QOLRAD domains of emotional
distress and vitality, indicating that omeprazole can
improve the psychological aspects of QOL in patients
with RE.
Conclusions
In this large-scale survey, omeprazole improved symp-
toms and QOL more effectively in Japanese patients
with RE than other investigated drugs, and had a good
tolerability profile.
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